New OpenBind consortium to make the UK a leader in AI-driven drug discovery-slashing the cost of drug discovery & development.. & MedChemica are at the heart of it! Click for the full gov.uk article and direct quote from our Technical Director @griffen-ed.bsky.social www.gov.uk/government/n...

Interesting piece from colleagues at @dndi.org and @medchemica.com on maximizing the potential for broad #access to #medicines being developed as #public #goods — #GlobalHealth #Equity #IP #Patents #Licensing — cen.acs.org/pharmaceutic...

Opinion: How patents can serve the common good

We want wide, fast, and affordable access for our new antiviral. It might sound counterintuitive, but a patent will help us do that

cen.acs.org

Lead medicinal chemist Ed Griffen (@griffen-ed.bsky.social) will be disclosing the new ASAP MERS-CoV/SARS-CoV-2 oral antiviral at @acs.org on Tue 25 Mar! Tune in to this virtual session to hear about its discovery and development! acs.digitellinc.com/live/34/sess...

Enamine Ltd | @medchemica.com | PostEra | @jchodera.bsky.social | @diamondlightsource.bsky.social | @mountsinainyc.bsky.social | Weizmann Institute

📢Important announcement! Today, the @asapdiscovery.bsky.social consortium disclosed the structure of our preclinical candidate, ASAP-0017445, a promising broad-spectrum antiviral with potent activity against SARS-CoV2 and other viruses belonging to the same family. (1/10)

5 weeks to go🚀 @griffen-ed.bsky.social is presenting at the @conscience-network.bsky.social Symposium. Talk Title; "Balancing Open Science and Intellectual Property to Discover and Develop Medicines” @asapdiscovery.bsky.social Register now: conscience.ca/symposium202...

5 weeks to go! 🚀 Dr @griffen-ed.bsky.social is presenting at the ACS Spring Meeting & Expo. Talk Title; “Discovery of non-peptidomimetic oral combined MERS and SARS-CoV-2 anti-virals." @asapdiscovery.bsky.social @acs.org #ACSSpring2025 Click to register 🔗 www.acs.org/meetings/acs...

3 weeks to go🚀 @griffen-ed.bsky.social is presenting at #ICAR2025 the highlights of the discovery, in vitro and in vivo profile of the ASAP AViIDD Center’s pre-clinical candidate for treating 6 lethal coronavirus infections: ASAP-0017445. Register now 🔗 lnkd.in/gbBRZSz2 @asapdiscovery.bsky.social

Who is attending the 'Chemist In Industry' SCI conference at Alderley Park tomorrow? Our very own Dr @aldossetter.bsky.social is presenting an insightful talk on ‘Addressing ‘The Big Two.’ – Intrigued? You should be! See you all there! #SCI #ChemistInIndustry #DrugDiscovery #DrugDesign

@thesgc.bsky.social @medchemica.com @asapdiscovery.bsky.social

Don't miss our very own Dr Ed Griffen @griffen-ed.bsky.social giving a talk today at the AViDD Open Science Forum...

The ASAP Discovery Consortium@asapdiscovery.bsky.social · 2y ago

Tune in Wed 20 Nov at 11A ET for our Antiviral Drug Discovery Open Science Forum to hear Ed Griffen (@griffen-ed.bsky.social) [MedChemica @medchemica.bsky.social] and Pascale Boulet [DNDi @dndi.bsky.social] discuss enabling affordable access with creative IP agreements! asapdiscovery.org/forum/